Gain the Decision Advantage
Breakthrough 2027 brings together life sciences leaders, industry regulators and experts, to explore the future of AI in life sciences.
A multinational tobacco products manufacturing company recently selected ArisGlobal’s LifeSphere® MultiVigilance 10, industry’s first and only automated adverse event platform for their global safety vigilance needs.
Linical a market-leading, midsized, global contract research organization (CRO) adopted ArisGlobal’s LifeSphere MultiVigilance as their primary global safety management system, industry’s first and only automated adverse event platform.
ArisGlobal announced it has made a number of new key leadership hires, with the express purpose of preparing for accelerated growth in North America, Europe, and Asia, and new product launches in 2020, according to President and CEO Sankesh Abbhi.
ArisGlobal has expanded its partnership with Soterius, Inc., a global leader in providing drug safety and medical outsourcing services and solutions adding LifeSphere® MultiVigilance and LifeSphere® Medical Information to their service-oriented technology stack.
ArisGlobal successfully delivered the industry’s largest drug safety system implementation, going live on-time with its next-generation LifeSphere® MultiVigilance offering. LifeSphere MultiVigilance 10 is the industry’s only end-to-end safety system offering production-ready automation.
ArisGlobal is proud to announce that ten life sciences companies have switched to its industry-leading LifeSphere® MultiVigilance drug safety system within the past 12 months. LifeSphere MultiVigilance is a next-generation, end-to-end safety system that has been developed in close partnership with industry leaders, including the FDA, Boehringer Ingelheim, Teva and AbbVie, among others.
ArisGlobal, the visionary technology provider of automated solutions for the life sciences industry, today announced the availability of LifeSphere® LitPro (LSLP), the life science industry’s first and only solution that effectively automates all steps in the medical literature monitoring (MLM) process required by most regulatory agencies.
ArisGlobal, the visionary provider of drug development technology for the life sciences industry, today announced the availability of LifeSphere® MultiVigilance 10 (LSMV10), the industry’s only end-to-end drug safety system with production-ready automation.
Santen Pharmaceutical Co., Ltd., the leader in ophtalmicdrug development, has selected ArisGlobal to create a single global safety database and improve the efficiency and quality of their global safety vigilance processes. Santen Pharmaceutical’s safety suite will include ArisGlobal’s LifeSphere® MultiVigilance (LSMV), LifeSphere® Reporting and Analytics and LifeSphere® Intake and Triage solutions to automate key safety vigilance activities, reduce costs, and increase compliance.
ArisGlobal today announced details of its annual Life Sciences Technology Summit (AGLSTS 2019), taking place October 1st – 3rd at the Miami Beach EDITION hotel in Miami Beach, Florida. The 3-day event will bring together senior executives, IT and business practitioners, and industry experts across drug safety, regulatory affairs, clinical development, and medical affairs to discuss how a unified platform and automation technology can transform the drug development process.
ArisGlobal is a pivotal partner in the life sciences industry, specializing in solutions that drive drug development, safety monitoring, and regulatory compliance. We collaborate with more than 220 global life sciences companies, CROs, and government health authorities, including leading biopharmaceutical firms and regulatory bodies such as FDA, Health Canada, and NMPA.
Headquartered in the United States, ArisGlobal has regional offices in Europe, India, Japan and China.
Quick Links
© 2026 ArisGlobal – All Rights Reserved